EBOS Group, a $3.2 billion pharmacy wholesale supplier and pet care retailer listed in Australia and New Zealand, is emerging as a potential target for private equity acquisition, according to industry sources. Investment bankers have reportedly placed EBOS at the forefront of their pitch books, actively promoting the company to private equity firms as a “core-plus” investment opportunity.
EBOS is a leading marketer, wholesaler, and distributor of healthcare and pharmaceutical products across Australia and New Zealand. The company is currently led by CEO Adam Hall, who took over from John Cullity on July 1. Despite its prominent market position, EBOS shares have declined approximately 41 percent over the past year, prompting renewed interest from investors and potential acquirers.
The efforts to court private equity interest coincide with a notable wave of senior executive departures at the company’s Melbourne Docklands headquarters. Long-serving operations and innovation executive Simon Bunde was dismissed in September 2025, while strategy chief David Lewis and chief risk officer Leonard Hansen also left within the past year. More recently, head of investor relations Martin Krauskoph exited the firm, and Kristine James, who oversees EBOS’s medical technology division, is reportedly considering resignation. Some industry observers view these leadership changes as strategically timed amid takeover speculation.
A significant factor affecting EBOS’s recent performance was the loss of a major contract with Chemist Warehouse, valued at $1.1 billion annually, which ended in June 2024. Chemist Warehouse awarded the contract to its merger partner, Sigma, marking a substantial setback as this contract once represented about 17 percent of EBOS’s yearly revenue. Following this loss, EBOS has been actively seeking acquisition opportunities to bolster its business.
EBOS’s portfolio extends beyond wholesale pharmaceuticals. The company owns 50 percent of the New Zealand-based pet retailer Animates and generates roughly 10 percent of its annual earnings from Black Hawk Pet Food, a brand it owns. Additionally, EBOS operates the Terry White Chemmart pharmacy chain, which includes around 600 stores across Australia and New Zealand.
Geographically, Australia comprises approximately 65 percent of the company’s overall operations. EBOS controls about half of the community wholesale pharmacy market in Australia and roughly 30 percent in New Zealand, positioning it as the largest pharmaceutical wholesaler in the region.
As private equity interest intensifies, EBOS faces strategic decisions amid evolving market dynamics and executive turnover, with potential acquisition talks reflecting broader shifts in the pharmaceutical distribution and retail sector in Australasia.